Hussein Tawbi, MD, PhD, Discusses Results From the COMBI-AD Trial


Data from the COMBI-AD Trial evaluating dabrafenib and trametinib to treat melanoma was analyzed by Hussein Tawbi, MD, PhD, of The University of Texas MD Anderson Cancer Center.

CancerNetwork spoke with Hussein Tawbi, MD, PhD, to learn more regarding the results of the COMBI-AD trial presented at the SMR Conference examining dabrafenib and trametinib to treat resected stage 3 melanoma.


Clearly, when we find evidence of activity in the metastatic setting, we ask the question ‘can we bring it earlier into the disease and into earlier stages in which we may be able to cure patients, a larger proportion of patients?’ COMBI-AD was a study that was designed for patients with resected stage III melanoma that have evidence of BRAF mutation and was a 1 year of treatment with dabrafenib and trametinib compared to placebo. The study was positive, it showed a significant impact of dabrafenib and trametinib on decreasing the rate of relapse by almost a half, and the hazard ratio from the first time it was presented until now was basically between 0.47 and 0.52. So, there’s a very stable benefit over placebo and has been FDA approved and is the current standard of care.

What we’ve seen recently is more of the longer-term follow-up and some of the overall survival data being kind of complimented by the longer follow-up now. Simply stated, I think it does show that if you treat patients with dabrafenib and trametinib in the adjuvant setting, you decrease the risk of distant metastases, not just any recurrence but distant metastases, and that translates into what looks like a survival benefit. Again, it remains the standard of care and it remains quite comparable to immunotherapy in that setting.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Related Content